Summary:
This podcast delves into the critical challenges of scalability in T-cell therapies (including CAR-T, TILs, and TCR-T). The panelists discuss the primary obstacles hindering the increased availability of T-cell therapies to patients, the most promising upcoming approaches to enhance access, the greatest opportunities to improve efficiencies and scalability, and the developments in the near future that could help meet growing demand. This podcast comes from the 2025 Immuno-Oncology 360º Summit.
For more information, go to IO360summit.com
Speakers
Serena De Vita, MD, PhD
VP, Global Franchise Head and Global Clinical Strategy Head, Late Development Oncology, Cell Therapy
AstraZeneca
Arvind Natarajan, PhD, MBA
SVP, Process and Analytical Development
Iovance Biotherapeutics Inc
Greg Sawyer, PhD
Chief BioEngineering Officer, Chair, Department of BioEngineering
Moffitt Cancer Center
Sarah Warren, PhD
Senior Director, Corporate Development Lead, Cell Therapy Search and Evaluation
Kite Pharma / Gilead Sciences
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.